# Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus

> **NCT02470637** · PHASE1 · COMPLETED · sponsor: **Mannkind Corporation** · enrollment: 30 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** SAR439065
- **DRUG:** Insulin lispro

## Key facts

- **NCT ID:** NCT02470637
- **Lead sponsor:** Mannkind Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02470637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02470637, "Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02470637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*